SecBot SecBot
SECBOTREPLAY Home › Report › DAWN

DAWN · Day One Biopharmaceuticals reported strong 2025 financial results with…

Day One Biopharmaceuticals, Inc. · 8-K filed Feb 24, 2026 at 16:00 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 24, 2026 at 16:00 ET

Day One Biopharmaceuticals reported strong 2025 financial results with OJEMDA net product revenue of $155.4 million, representing 172% year-over-year growth. The company reaffirmed its 2026 U.S. net product revenue guidance of $225-$250 million, reflecting continued commercial momentum. R&D expenses decreased significantly year-over-year while prescription volume grew 181%, indicating strong market adoption.

  • OJEMDA net product revenue was $155.4 million for full year 2025, up 172% year-over-year
  • Fourth quarter 2025 revenue was $52.8 million
  • Total prescriptions in 2025 were 4,635, representing 181% growth versus 2024
  • Company reaffirmed 2026 U.S. net product revenue guidance of $225-$250 million

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access